journal article·2025-05-02

Biomimetic Hybrid Membrane-Cloaked Nanoparticles Assisted with Laser Irradiation for Synergistic Photothermal Immunotherapy of Fibrosarcoma

Yuan Ma, Zhao Wang, Xiaogang Xia, Lingwei Gu, Mengli Ma, Jialiang Zheng, Rubing Liang, Fenglin Miao, Zhenhang Lin, Yunjie Wang, Yilai Gao, Fanghong Luo, Wei Zeng, Wengang Li, Ting Wu

ACS Applied Nano Materials· Volume 8· Issue 17
Publisher page

Abstract

Fibrosarcoma is a malignant tumor of soft tissues that can occur in various parts of the body. Surgical resection remains the primary treatment, but local recurrence and metastasis are common after surgery. Due to the limited efficacy of surgical interventions and generally poor prognosis, immunotherapy has emerged as a strategy for treating fibrosarcoma. In this study, we fused WEHI-164 fibrosarcoma cell membranes with red blood cell (RBC) membranes to create a hybrid biomimetic coating (WRV). This hybrid membrane was used to encapsulate poly(lactic- co -glycolic) acid (PLGA) nanoparticles containing indocyanine green (ICG) and imiquimod (R837) (PLGA-ICG-R837@WRV, PIR@WRV) for synergistic photothermal and immunotherapy of fibrosarcoma. In a tumor-bearing mouse model, PIR@WRV effectively accumulated at the tumor site, producing superior photothermal effects and eradicating primary tumors. The induced hyperthermia enhanced tumor immunogenicity and facilitated the release of the immune adjuvant R837, further activating immune responses in the mice and simultaneously inhibiting the growth of distant tumors. Moreover, PIR@WRV combined with near-infrared (NIR) light demonstrated potential as a nanovaccine, providing long-term immune memory effects to prevent tumor recurrence. Our research presents a therapeutic strategy for the treatment of nontargeted fibrosarcoma, offering the potential to activate the immune system and inhibit tumor recurrence. This strategy also offers a straightforward and promising approach for treating metastatic cancers and preventing tumor recurrence.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cancer Research Center, School of Medicine

Xiamen University

Xiamen University School of Medicine, Cancer Research Center

Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University

Department of Basic Medicine, School of Medicine, Xiamen University, Xiang’an South Road, Xiang’an District, Xiamen 361000, China

Department of Gastroenterology

Department of Hepatobiliary Surgery

Funding

Natural Science Foundation of Fujian Province · National Natural Science Foundation of China · Xiamen University-Shanghai Jiangxia Blood Technology Co. Ltd · Xiamen University-Jiangsu Charity Biotech Co. Ltd · Provincial Public Welfare Project of Fujian Province

References (41)

Show source-provided references
1. 10.1080/14712598.2016.118807510.1080/14712598.2016.1188075 ↗
2. 10.1111/his.1228210.1111/his.12282 ↗
3. 10.1182/blood.V68.2.493.49310.1182/blood.V68.2.493.493 ↗
4. 10.1016/S1521-6926(02)00084-110.1016/S1521-6926(02)00084-1 ↗
5. 10.4049/jimmunol.149001910.4049/jimmunol.1490019 ↗
6. 10.1002/smll.20200170410.1002/smll.202001704 ↗
7. 10.1038/s41467-019-09760-310.1038/s41467-019-09760-3 ↗
8. 10.1016/j.msec.2019.10989110.1016/j.msec.2019.109891 ↗
9. 10.1021/acsami.9b0956810.1021/acsami.9b09568 ↗
10. 10.1016/j.biomaterials.2019.02.01410.1016/j.biomaterials.2019.02.014 ↗
11. 10.1039/D1BM00526J10.1039/D1BM00526J ↗
12. 10.1002/anie.20150615410.1002/anie.201506154 ↗
13. 10.1016/j.ctrv.2015.05.00910.1016/j.ctrv.2015.05.009 ↗
14. 10.1002/advs.20200250410.1002/advs.202002504 ↗
15. 10.1002/adma.20130189010.1002/adma.201301890 ↗
16. 10.1016/j.biomaterials.2018.11.02110.1016/j.biomaterials.2018.11.021 ↗
17. 10.1038/ncomms1319310.1038/ncomms13193 ↗
18. 10.1164/rccm.200908-1255OC10.1164/rccm.200908-1255OC ↗
19. 10.1002/adma.20170675910.1002/adma.201706759 ↗
20. 10.1021/acsnano.6b0647710.1021/acsnano.6b06477 ↗
21. 10.1002/adma.20160217310.1002/adma.201602173 ↗
22. 10.1002/adma.20150608610.1002/adma.201506086 ↗
23. 10.1016/j.cej.2023.14249510.1016/j.cej.2023.142495 ↗
24. 10.1021/acsami.4c1741310.1021/acsami.4c17413 ↗
25. 10.1021/acsami.4c0533410.1021/acsami.4c05334 ↗
26. 10.1021/acs.accounts.4c0003110.1021/acs.accounts.4c00031 ↗
27. 10.34133/bmr.015110.34133/bmr.0151 ↗
28. 10.1039/D3CS00926B10.1039/D3CS00926B ↗
29. 10.1002/advs.20241288110.1002/advs.202412881 ↗
30. 10.1021/acsami.3c0737910.1021/acsami.3c07379 ↗
31. 10.1021/acsnano.1c0718010.1021/acsnano.1c07180 ↗
32. 10.1021/acsnano.8b0737110.1021/acsnano.8b07371 ↗
33. 10.1016/j.apsb.2019.01.01110.1016/j.apsb.2019.01.011 ↗
34. 10.1021/acs.bioconjchem.6b0056910.1021/acs.bioconjchem.6b00569 ↗
35. 10.1039/c3nr03064d10.1039/c3nr03064d ↗
36. 10.1021/acsnano.7b0253310.1021/acsnano.7b02533 ↗
37. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
38. 10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
39. 10.1016/j.jconrel.2020.10.06010.1016/j.jconrel.2020.10.060 ↗
40. 10.1038/s41551-018-0236-810.1038/s41551-018-0236-8 ↗
41. 10.1002/advs.20210184010.1002/advs.202101840 ↗